Microcephaly, Fanconi Anemia and Praxial Disorders

NCT ID: NCT04656171

Last Updated: 2023-02-03

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-30
• Study Completion Date: 2023-01-30

Brief Summary

Fanconi Anemia (FA) is mentioned in children with congenital malformations including kidney, hart and skeletal malformations (absence or abnormal thumb or forearm), and bone marrow failure or myelodysplasia with a progressive onset in childhood or adulthood. No study has focused on microcephaly, a reduction in brain volume, which is present in 20% of children, and its consequences on cognitive and structural level of the brain. Since 2014, Robert-Debré's team has been interested in this functional cognitive and neuroanatomical approach trough a National PHRC. Preliminary results carried out on 12 children show that their intellectual efficiency was in the normal range for age. However, we noticed a significant difference between abilities in comprehension and verbal reasoning corresponding to what is expected for age, and the sensorimotor skills or fine motor praxia significantly reduced. These difficulties, graphically penalizing for these children, are not always explained by a skeletal malformation of the upper limb, suggesting that musculo-tendinous anomalies may be associated. The objectives of our project are: 1) to identify upper limb musculo-tendinous abnormalities and their functional consequences, 2) to determine if these abnormalities could influence the somatosensory representation of the upper limb at the cerebral cortical level. This project should help us to better understand the fine motor disabilities or developmental coordination disorder of these children, which penalize their learning, and provide them with adapted solutions.

Detailed Description

Our hypothesis is that children with FA present a developmental dyspraxia. This condition is very penalizing for children especially regarding graphic tasks, handwriting, whether or not they have skeletal malformations of the upper limbs. Consequences are fatigue because of energy expended trying to execute fine motor movements correctly.

Main objective:

To identify gesture dyspraxia in order to propose a targeted rehabilitation leading to national recommendations.

Main Evaluation Criteria :

1. measurement of fine motor praxia

2. quantification of dyspraxia

Secondary Objectives :

To identify the musculoskeletal or tendinous anomalies in the upper limbs of AF children and to assess their functional consequences.

To determine if these upper limbs abnormalities could influence the somatosensory map of this part of the body in the cerebral cortex.

Secondary Evaluation Criteria :

1. MRI of the hand and forearm, orthopedic examination and functional assessment

2. Previously obtained brain MRI data

Conditions

Fanconi Anemia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Minor patients with Fanconi anemia

MRI of hands and forearm, neuropsychological and neuromotor tests

Group Type: EXPERIMENTAL

MRI of the hand and forearm,

Intervention Type: RADIATION

MRI of the hand and forearm,

Minor controls

MRI of the hand and forearm, orthopedic evaluation, neuromotor tests of the upper limbs, praxies evaluation, neurocognitive evaluation

Group Type: ACTIVE_COMPARATOR

MRI of the hand and forearm,

Intervention Type: RADIATION

MRI of the hand and forearm,

Interventions

MRI of the hand and forearm,

MRI of the hand and forearm,

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

1. Patients with Fanconi Anemia defined according to two of the following diagnostic criteria already included in the MicroFanc study:

• Chromosome breakage test after exposure to an alkylating agent (mitomycin) on peripheral blood lymphocytes.
• FancD2 test on lymphocytes or fibroblasts
• sensitivity of fibroblasts to mitomycin
• mutation in one of the FANC complementation genes (A, B, C, D1, D2, E, F, G, I, J, L, M, N)

2. Non-transplanted patients or patients at a distance from CSH transplant (>3 years)

3. Age ≥5 years of age at inclusion (minimum age of accessibility for neuropsychological tests and no need for sedation for MRI)

Exclusion Criteria

Subjects for whom both parents have not agreed to participate in the research, or for whom MRI is contraindicated.

• Minimum Eligible Age: 5 Years
• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sandrine Passemard, MD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Robert Drbré Hospital

Paris, , France

Countries

France

Other Identifiers

N° IDRCB: 2019-A03171-56

Identifier Type: REGISTRY

Identifier Source: secondary_id

APHP200090

Identifier Type: -

Identifier Source: org_study_id